Építés alatt – nem éles oldal
Belépés
VisszavonvaKorai 1. fázis

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease

A legfontosabb adatok

Ki végzi
Weill Medical College of Cornell University
Hol
New York (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
Korai 1. fázis
Kezdés
2021. dec.
Befejezés
2024. jún.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Selinexor
  • Dexamethasone
A regiszteradat frissítve
2022. november 17.
Miért állt le
Funding withdrawn

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 27 feltétel megnézéseKevesebb

Ki vehet részt

  • Diagnosis of primary AL amyloidosis
  • Relapsed and/or refractory AL amyloidosis
  • Measurable disease
  • Male or female patients 18 years or older
  • Able to give voluntary written consent
  • Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2
  • Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3
  • Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN
  • Calculated creatinine clearance ≥ 30 mL/min

Ki nem vehet részt

  • Prior exposure to Selinexor
  • Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment
  • Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy
  • Major surgery within 14 days before enrollment
  • Radiotherapy within 14 days before enrollment
  • Infection requiring systemic intravenous antibiotic therapy or other serious infection within 14 days before study enrollment. Systemic treatment, within 14 days before the first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba or St. John's wort
  • Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
  • Participation in another clinical trials involving investigational agents within 30 days of starting this trial
  • Clinically significant cardiac disease
  • Severe obstructive airway disease
  • Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
  • Serious medical or psychiatric illness
  • GI disease or GI procedure that could interfere with the oral absorption or tolerance including difficulty swallowing
  • Female patients who are lactating or have a positive serum pregnancy test during the screening period
  • Non-AL amyloidosis
  • Clinically overt myeloma
  • Peripheral neuropathy (grade 2 with pain or grade 3 or higher)

Helyszínek itt: Egyesült Államok

  • Weill Cornell Medicine - Multiple Myeloma CenterNew York, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to test the safety and efficacy of Selinexor and Dexamethasone and see what effects it has on AL amyloidosis.

A vizsgálat csoportja

  • selinexor/ dexamethasone (Sd)A vizsgált kezelés

    Selinexor • 60mg PO once weekly on days 1, 8, 15, 22 until disease progression or toxicity Dexamethasone • 20 mg PO administered 30-60 minutes prior to selinexor on days 1, 2, 8, 9, 15, 16, 22, 23

    Kezelés: Selinexor és Dexamethasone

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2022. november 17.